{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:13:09Z","timestamp":1771002789577,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.jcjo.2015.03.009","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T06:08:41Z","timestamp":1438841321000},"page":"297-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Carbonic anhydrase inhibitors as fourth drug in primary glaucomas: Is it worth it?"],"prefix":"10.1016","volume":"50","author":[{"given":"Verena Ribeiro","family":"Juncal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Abdo Jorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Augusto","family":"Paranhos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago","family":"Santos Prata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2015.03.009_bib1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.03.009_bib2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archopht.120.6.714","article-title":"The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma","volume":"120","author":"Gordon","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.03.009_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.03.009_bib4","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","article-title":"Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery","volume":"108","author":"Lichter","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2015.03.009_bib5","unstructured":"Allingham RR, Damji KF, Freedman S, Moroi SE, Rhee DJ. Shields Textbook of Glaucoma. 6th ed. New York: Lippincott Williams & Wilkins; 2001"},{"key":"10.1016\/j.jcjo.2015.03.009_bib6","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0161-6420(96)30407-7","article-title":"a prostaglandin analog, for glaucoma therapy: efficacy and safety after 1 year treatment in 198 patients","volume":"103","author":"Camras","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2015.03.009_bib7","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archopht.120.10.1286","article-title":"One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension","volume":"120","author":"Higginbotham","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.03.009_bib8","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0161-6420(95)30798-1","article-title":"Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol","volume":"102","author":"Alm","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2015.03.009_bib9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0002-9394(01)01177-1","article-title":"Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension","volume":"132","author":"Netland","year":"2001","journal-title":"Am J Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.jcjo.2015.03.009_bib10","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0039-6257(96)82029-7","article-title":"Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension","volume":"41","author":"Schuman","year":"1996","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.03.009_bib11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/archopht.1995.01100080061030","article-title":"A Double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol","volume":"113","author":"Strahlman","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.03.009_bib12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0002-9394(00)00381-0","article-title":"Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure","volume":"129","author":"Stewart","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.03.009_bib13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ophtha.2007.10.004","article-title":"Meta-analysis of 24-hour intraocular pressure studies evaluation the efficacy of glaucoma medicines","volume":"115","author":"Stewart","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2015.03.009_bib14","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/bjo.2003.032979","article-title":"Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension","volume":"88","author":"Sharpe","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 11","key":"10.1016\/j.jcjo.2015.03.009_bib15","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ophtha.2009.06.024","article-title":"A comprehensive perspective on patient adherence to topical glaucoma therapy","volume":"116","author":"Tsai","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2015.03.009_bib16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0149-2918(01)80064-3","article-title":"Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension","volume":"23","author":"Simmons","year":"2001","journal-title":"Clin Ther."},{"key":"10.1016\/j.jcjo.2015.03.009_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0002-9394(01)00974-6","article-title":"Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension","volume":"132","author":"Michaud","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.03.009_bib18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0149-2918(04)90075-6","article-title":"Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America","volume":"26","author":"Susanna","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.jcjo.2015.03.009_bib19","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(04)16257-0","article-title":"Primary open-angle glaucoma","volume":"363","author":"Weinreb","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jcjo.2015.03.009_bib20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0039-6257(98)00049-6","article-title":"Ophthalmoscopic evaluation of the optic nerve head","volume":"43","author":"Jonas","year":"1999","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.03.009_bib21","series-title":"Glaucoma","first-page":"172","year":"2010"},{"key":"10.1016\/j.jcjo.2015.03.009_bib22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0149-2918(00)89008-6","article-title":"Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma","volume":"22","author":"Simmons","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.jcjo.2015.03.009_bib23","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.ophtha.2009.10.038","article-title":"Intentional and unintentional nonadherecnce to ocular hypotensive treatment in patients with glaucoma","volume":"117","author":"Rees","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2015.03.009_bib24","doi-asserted-by":"crossref","unstructured":"Loon SC, Jin J, Jin Goh M. The relationship between quality of life and adherence to medication in glaucoma patients in Singapore. J Glaucoma. 2015;24:36-42.","DOI":"10.1097\/IJG.0000000000000007"},{"key":"10.1016\/j.jcjo.2015.03.009_bib25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000356468","article-title":"Improvement in glaucoma patient quality of life by therapy switch to preservative-free timolol\/dorzolamide fixed combination","volume":"231","author":"Pinto","year":"2014","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jcjo.2015.03.009_bib26","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","article-title":"Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications","volume":"29","author":"Fechtner","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2015.03.009_bib27","unstructured":"Li P, Park SC, Huang G, Liebmann JM, Ritch R. Clinical significance of a third or fourth anti-glaucoma eye drop. Poster session presented at. The Association for Research in Vision and Ophthalmology. May 4-8, 2014"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418215001556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418215001556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:04:22Z","timestamp":1757793862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418215001556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0008418215001556"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2015.03.009","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carbonic anhydrase inhibitors as fourth drug in primary glaucomas: Is it worth it?","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2015.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}